hydroxychloroquine has been researched along with Bradyarrhythmia in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| " During the hospitalization, she experienced unexpected sinus bradycardia with prolonged QTc, which was thought to be closely related to the short-term use of hydroxychloroquine (HCQ), an old drug used to treat malaria and autoimmune diseases, but now used against COVID-19." | 7.96 | Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19. ( Chen, H; Kang, Y; Ran, Q; Wang, B; Wang, H; Wei, J; Yang, Y; Zhao, X, 2020) |
| " During the hospitalization, she experienced unexpected sinus bradycardia with prolonged QTc, which was thought to be closely related to the short-term use of hydroxychloroquine (HCQ), an old drug used to treat malaria and autoimmune diseases, but now used against COVID-19." | 3.96 | Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19. ( Chen, H; Kang, Y; Ran, Q; Wang, B; Wang, H; Wei, J; Yang, Y; Zhao, X, 2020) |
| "The purpose of this study was to investigate the propensity of hydroxychloroquine (HCQ) to cause bradycardia." | 3.81 | Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential. ( Bub, G; Burton, RA; Capel, RA; Channon, K; Douglas, G; Herring, N; Kalla, M; Mirams, GR; Paterson, DJ; Terrar, DA; Yavari, A, 2015) |
| "The incidence and nature of arrhythmias in the setting of COVID-19 were poorly documented across studies." | 2.72 | Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. ( Amarasekera, AT; Kayes, T; Kodsi, M; MacIntyre, CR; Malaty, M; Tan, TC, 2021) |
| " Hydroxychloroquine (HCQ)-associated cardiovascular adverse events (CVAEs) have been increasingly reported." | 1.72 | An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19. ( Li, Y; Luo, M; Wu, B; Wu, F, 2022) |
| " For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens, and the possible negative effect of HCQ on the antiviral type-I interferon response." | 1.56 | It is time to drop hydroxychloroquine from our COVID-19 armamentarium. ( Kashour, T; Tleyjeh, IM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 6 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, M | 1 |
| Wu, B | 1 |
| Li, Y | 1 |
| Wu, F | 1 |
| Jiang, RJ | 1 |
| Jia, J | 1 |
| Du, Y | 1 |
| Zhang, HS | 1 |
| Millá Griñó, E | 1 |
| Muniesa Royo, MJ | 1 |
| Pazos López, M | 1 |
| Kang, Y | 1 |
| Wang, H | 1 |
| Chen, H | 1 |
| Wang, B | 1 |
| Yang, Y | 1 |
| Zhao, X | 1 |
| Ran, Q | 1 |
| Wei, J | 1 |
| Malaty, M | 1 |
| Kayes, T | 1 |
| Amarasekera, AT | 1 |
| Kodsi, M | 1 |
| MacIntyre, CR | 1 |
| Tan, TC | 1 |
| Kashour, T | 1 |
| Tleyjeh, IM | 1 |
| Capel, RA | 1 |
| Herring, N | 1 |
| Kalla, M | 1 |
| Yavari, A | 1 |
| Mirams, GR | 1 |
| Douglas, G | 1 |
| Bub, G | 1 |
| Channon, K | 1 |
| Paterson, DJ | 1 |
| Terrar, DA | 1 |
| Burton, RA | 1 |
| de Jong-Straková, Z | 1 |
| Blaauw, AA | 1 |
| van der Linden, SJ | 1 |
| Ferwerda, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hydroxychloroquine and Bradyarrhythmia
| Article | Year |
|---|---|
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Atrial Fibrillat | 2021 |
7 other studies available for hydroxychloroquine and Bradyarrhythmia
| Article | Year |
|---|---|
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Topics: Arrhythmias, Cardiac; Bradycardia; Cardiac Conduction System Disease; Cardiovascular System; COVID-1 | 2022 |
Sinus bradycardia and heart failure induced by short-term use of low-dose hydroxychloroquine: A case report.
Topics: Bradycardia; Heart Failure; Humans; Hydroxychloroquine | 2023 |
[Therapeutic conflict in patients with COVID-19 and glaucoma].
Topics: Adrenergic beta-Antagonists; Antimalarials; Betacoronavirus; Bioaccumulation; Bradycardia; Coronavir | 2020 |
Suspected Hydroxychloroquine-Induced Sinus Bradycardia and QTc Prolongation in a Patient with COVID-19.
Topics: Aged, 80 and over; Betacoronavirus; Bradycardia; Coronavirus Infections; COVID-19; COVID-19 Drug Tre | 2020 |
It is time to drop hydroxychloroquine from our COVID-19 armamentarium.
Topics: Animals; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Bradycardia; COVID-19 Drug Treatment; | 2020 |
Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potential.
Topics: Action Potentials; Animals; Bradycardia; Disease Models, Animal; Electrophysiological Phenomena; Enz | 2015 |
[A patient with acute hydroxychloroquine poisoning; recommendation for treatment].
Topics: Adult; Bradycardia; Critical Care; Gastric Lavage; Humans; Hydroxychloroquine; Hypotension; Male; Re | 1990 |